CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands		Total	Series E	Series B	Series D	Common Stock		Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series E convertible preferred stock (in shares)			167,273,525
Preferred stock, beginning balance (in shares) at Dec. 31, 2020	[1]	957,159,704
Preferred stock, beginning balance at Dec. 31, 2020		$ 2,494,076
Increase (Decrease) in Temporary Equity [Roll Forward]
Repurchase of convertible preferred stock (in shares)	[1]			(3,525,365)
Issuance of Series D convertible preferred shares upon exercise of warrants (in shares)	[1]				1,546,799
Issuance of Series D convertible preferred stock upon exercise of warrants					$ 12,936
Issuance of Series E convertible preferred stock (in shares)	[1]		200,728,229
Issuance of Series E convertible preferred stock			$ 3,206,159
Stock-based compensation related to Series E convertible preferred stock			123,614
Preferred stock, ending balance (in shares) at Jun. 30, 2021	[1],[2]	1,155,909,367
Preferred stock, ending balance at Jun. 30, 2021		$ 5,836,785
Beginning balance (in shares) at Dec. 31, 2020	[1]					28,791,702
Beginning balance at Dec. 31, 2020		(1,318,777)				$ 3		$ 38,113			$ (1,356,893)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(1,009,678)									(1,009,678)
Net unrealized losses on investments, net of tax		0
Issuance of Series E convertible preferred stock		(2,151,613)						(22,396)			(2,129,217)
Issuance of common stock upon exercise of stock options (in shares)	[1]					8,007,448
Issuance of common stock upon exercise of stock options		5,266						5,266
Stock-based compensation		5,630						5,630
Ending balance (in shares) at Jun. 30, 2021	[1],[2]					36,799,150
Ending balance at Jun. 30, 2021		$ (4,469,172)				$ 3		26,613			(4,495,788)
Preferred stock, beginning balance (in shares) at Mar. 31, 2021	[2]	1,088,999,959
Preferred stock, beginning balance at Mar. 31, 2021		$ 4,454,811
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series E convertible preferred stock (in shares)	[2]	66,909,408
Issuance of Series E convertible preferred stock		$ 1,361,273
Stock-based compensation related to Series E convertible preferred stock			$ 20,701
Preferred stock, ending balance (in shares) at Jun. 30, 2021	[1],[2]	1,155,909,367
Preferred stock, ending balance at Jun. 30, 2021		$ 5,836,785
Beginning balance (in shares) at Mar. 31, 2021	[2]					35,689,218
Beginning balance at Mar. 31, 2021		(4,227,863)				$ 3		6,196			(4,234,062)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(261,726)									(261,726)
Net unrealized losses on investments, net of tax		0
Issuance of Series E convertible preferred stock		15,719						15,719
Issuance of common stock upon exercise of stock options (in shares)	[2]					1,109,932
Issuance of common stock upon exercise of stock options		950						950
Stock-based compensation		3,748						3,748
Ending balance (in shares) at Jun. 30, 2021	[1],[2]					36,799,150
Ending balance at Jun. 30, 2021		$ (4,469,172)				$ 3		26,613			(4,495,788)
Preferred stock, beginning balance (in shares) at Jul. 22, 2021		437,182,072
Beginning balance (in shares) at Jul. 22, 2021		451,295,965
Ending balance (in shares) at Jul. 23, 2021		1,618,621,534
Preferred stock, beginning balance (in shares) at Dec. 31, 2021		0
Preferred stock, ending balance (in shares) at Jun. 30, 2022		0
Beginning balance (in shares) at Dec. 31, 2021		1,647,555,590				1,647,555,590	[1]
Beginning balance at Dec. 31, 2021		$ 3,909,355				$ 165		9,995,778	$ (20,716)	$ 0	(6,065,872)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(301,711)									(301,711)
Net unrealized losses on investments, net of tax		(691)								(691)
Issuance and sale of common stock for tax withholdings of employee RSUs		(191,241)						(191,241)
Issuance of common stock upon vesting of employee RSUs (in shares)	[1]					8,041,659
Issuance of common stock upon vesting of employee RSUs		0				$ 1		(1)
Issuance of common stock under employee stock purchase plan (in shares)	[1]					751,036
Issuance of common stock under employee stock purchase plan		$ 12,882						12,882
Issuance of common stock upon exercise of stock options (in shares)		16,195,326				16,195,326	[1]
Issuance of common stock upon exercise of stock options		$ 12,849				$ 1		12,848
Stock-based compensation		$ 268,943						268,943
Ending balance (in shares) at Jun. 30, 2022		1,672,543,611				1,672,543,611	[1],[2]
Ending balance at Jun. 30, 2022		$ 3,710,386				$ 167		10,099,209	(20,716)	(691)	(6,367,583)
Preferred stock, ending balance (in shares) at Jun. 30, 2022		0
Beginning balance (in shares) at Mar. 31, 2022	[2]					1,666,739,708
Beginning balance at Mar. 31, 2022		$ 3,829,469				$ 167		9,997,176	(20,716)	0	(6,147,158)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(220,425)									(220,425)
Net unrealized losses on investments, net of tax		(691)								(691)
Issuance and sale of common stock for tax withholdings of employee RSUs		(8,976)						(8,976)
Issuance of common stock upon vesting of employee RSUs (in shares)	[2]					960,651
Issuance of common stock upon vesting of employee RSUs		0
Issuance of common stock under employee stock purchase plan (in shares)	[2]					751,036
Issuance of common stock under employee stock purchase plan		12,882						12,882
Issuance of common stock upon exercise of stock options (in shares)	[2]					4,092,216
Issuance of common stock upon exercise of stock options		3,735						3,735
Stock-based compensation		$ 94,392						94,392
Ending balance (in shares) at Jun. 30, 2022		1,672,543,611				1,672,543,611	[1],[2]
Ending balance at Jun. 30, 2022		$ 3,710,386				$ 167		$ 10,099,209	$ (20,716)	$ (691)	$ (6,367,583)

[1] The number of shares of convertible preferred stock and common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 - Description of Business and Note 3 - Reverse Capitalization for more information.

[2] The number of shares of convertible preferred stock and common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 “Description of Business” and Note 3 “Reverse Capitalization” for more information.